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Introduction
According to the US Census Bureau’s 2017 National Population 
Projections, there will be 78 million people 65 years or older in 
the US by 20351. Elderly people are a growing part of surgical 
caseloads2.
Also, with increasing age, the prevalence of ischemic heart 
disease increases. Ischemic heart disease is one of the leading 
causes of death worldwide3. Similarly, the prevalence of type 2 
diabetes mellitus increases in the proportion of people older than 
65 years of age4. Cardiovascular disease, especially ischemic 
heart disease, is an important risk factor of morbidity and 
mortality in patients with diabetes5.
In this review, we outline recent cardioprotective strategies 
in patients with diabetes and in the elderly and discuss 
their eventual application in the perioperative setting. For a 
complete overview of the cardioprotective effects of routinely 
used anesthetics and other pharmacological agents commonly 
used in the perioperative period, we encourage the reader to 
address other systematic and narrative reviews in this field6–14.
Type 2 diabetes mellitus
Ischemia-reperfusion injury and cardioprotection in 
diabetes
Reperfusion of the ischemic myocardium is the main key to 
saving tissue. Nevertheless, reperfusion may result in harmful 
effects, known as reperfusion injury. The main mechanisms 
involved in the pathogenesis of reperfusion injury are calcium 
overload and oxidative stress with the production of reactive 
oxygen species. Other mechanisms are mitochondrial dysfunc-
tion, inflammation, apoptosis, endoplasmic reticulum stress, and 
protein kinase activation15,16.
Patients with diabetes seem especially vulnerable to the effects 
of myocardial ischemia-reperfusion injury. The exact under-
lying mechanisms are not fully known but an increased basal 
oxidative stress due to excessive reactive oxygen species 
production or reduced endogenous antioxidant defense system 
or both seem to play an important role17. The enhanced basal 
oxidative stress is thought to be the result of chronic hyper-
glycemia. Chronic hyperglycemia as such severely impacts 
the ischemic myocardium. It is associated with endothelial 
dysfunction, impairs the development of coronary collateral 
blood flow, and attenuates the dilatation of coronary microcir-
culation in response to ischemia and to increased myocardial 
oxygen consumption18. In addition, animal and human data 
support the concept that ischemic and anesthetic cardioprotec-
tive strategies are not effective in diabetic hearts19–23. Hyper-
glycemia further impairs the pharmacological activation of 
mitochondrial ATP-dependent potassium (K
ATP
) channels, 
responsible for preconditioning effects24. Moreover, many 
patients with diabetes take sulfonylurea hypoglycemic agents 
which close the K
ATP
 channels. As activation of these channels 
is one of the mechanisms that protect the myocardium against 
ischemia-reperfusion injury, its blocking may explain the 
impaired cardioprotective effects of preconditioning strategies 
observed in many patients with diabetes.
Metformin and its cardioprotective actions
Metformin is an oral anti-diabetic drug that is widely used 
in patients with diabetes. Its glucose-lowering effects result 
from various actions: inhibition of complex I of the mitochon-
drial respiratory chain, decreased hepatic glucose production, 
increased glucose reuptake, and stimulation of adenosine 
monophosphate-activated protein kinase (AMPK)25. The main 
concern with the use of metformin in the perioperative period 
has been the development of lactic acidosis.
Interestingly, recent data show evidence for cardioprotective 
effects of metformin26. The main action of metformin seems to 
be via activation of AMPK, which increases tolerance against 
ischemia-reperfusion injury. Activation of AMPK further results 
in phosphorylation of endothelial nitric oxide synthase (eNOS), 
increasing nitric oxide (NO) bioavailability and preventing 
mitochondrial permeability transition pore (mPTP) opening 
at reperfusion. Regulation of endothelial and myocardial NO 
synthesis by multi-site eNOS phosphorylation seems to be 
essential in the pathophysiology of different cardiovascular 
diseases and explains the beneficial effects on ischemia- 
reperfusion injury and heart failure27. In addition, metformin 
stimulates intracellular formation of adenosine. Adenosine 
receptor stimulation activates the reperfusion injury salvage 
kinase (RISK) pathway, which in turn contributes to eNOS 
phosphorylation and prevents opening of mPTP28,29. Although 
beneficial effects of metformin on ischemia-reperfusion 
injury have been extensively shown in various small-animal 
models30–35, such effects could not be reproduced in swine 
models36.
This is another example that data obtained on rodents should be 
confirmed by similar findings in larger-animal models before 
translating them into human research37–39.
They, moreover, highlight the influence of anesthetic agents 
when used in cardioprotective research. Indeed, in the study by 
Techiryan et al.36, the pigs were maintained anesthetized with 
a continuous infusion of propofol. In a rat model, sevoflurane 
in the presence of low sedative propofol concentrations 
completely lost its protection40. Otherwise, propofol has been 
shown to interfere with the cardioprotective mechanisms 
induced by remote ischemic preconditioning (RIPC)41,42. It is 
therefore plausible that propofol also interferes with other forms 
of cardioprotection.
Metformin and clinical outcome data
Given its theoretical cardioprotective effects, metformin has 
been extensively studied in recent years. Many prospective and 
retrospective studies have shown the efficacy of metformin in 
decreasing cardiovascular events, mortality, and hospital 
readmission rates in patients with heart failure and diabetes43–49 
and in patients with coronary artery disease and diabetes50–54. 
In non-diabetic patients, however, metformin seemed not to be 
associated with any beneficial effects in terms of cardiovascular 
outcome55–59. Whether in clinical practice the cardioprotective 
properties of metformin are more pronounced in diabetic 
hearts should be further investigated.
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Otherwise, the positive effects of metformin were mostly 
obvious when it was used as chronic treatment. In trials where 
metformin was solely started before the initiation of the study, 
no beneficial effects could be observed.
In clinical practice, chronic metformin therapy in diabetic 
patients presenting for surgery is stopped because of the fear of 
perioperative lactic acidosis. In the era of perioperative cardio-
protection, it is questionable whether this is justified. So far, no 
studies have investigated this issue.
Newer anti-hyperglycemic medications and cardiovascular 
outcome data
Sodium-glucose cotransporter-2 inhibitors and glucagon-like 
peptide-1 receptor agonists are two new classes of anti- 
hyperglycemic agents60,61. Sodium-glucose cotransporter-2 
inhibitors function by increasing urinary excretion of glucose 
in the renal tubules. Glucagon-like peptide-1 receptor agonists 
execute their function on the basis of the incretin effect, a 
response to release more insulin because of high glucose levels 
after a meal. The cardiovascular safety of both agents has been 
extensively evaluated in recent years. Although the results of 
randomized controlled trials with these new agents show 
cardiovascular safety, their beneficial effects in terms of 
cardiovascular outcome warrant further investigation62,63.
Remote ischemic preconditioning and diabetes
RIPC is a technique during which brief periods of ischemia in a 
remote vascular bed provide protection against ischemia-
reperfusion injury in different parenchymal organs. The 
most studied organ so far is the heart. It is beyond the scope 
of this review to discuss the putative mechanisms involved 
and the conflicting results of clinical trials on RIPC. The 
interested reader is referred to different review articles on the 
topic9,64–67. The CONDI 2/ERIC-PPCI trial (ClinicalTrials.
gov Identifier: NCT02342522), a large European multicenter 
study, is investigating whether remote ischemic conditioning 
prior to percutaneous coronary intervention in patients with 
ST-segment elevation myocardial infarction will decrease the 
rates of cardiac mortality and hospitalization for heart failure at 
12 months.
Whether RIPC can have any positive influence on the 
diabetic myocardium has been evaluated in only a few trials. 
One of the studies that have specifically addressed this issue 
is a retrospective analysis68 which showed that RIPC has no 
cardioprotective effects in patients with diabetes and may even 
be deleterious in those diabetics who received sulfonylurea 
hypoglycemic agents.
Recently, the EUROpean and Chinese Cardiac and Renal 
Remote Ischemic Preconditioning Study (EURO-CRIPS) has 
sought to determine whether RIPC could be cardioprotective 
in the presence of diabetes69. Among 223 patients who under-
went a percutaneous coronary intervention, 38% had diabetes 
mellitus. Periprocedural myocardial infarction occurred in a 
significantly higher number of patients with diabetes in the 
control group compared with the RIPC group.
The Effect of Remote Ischaemic Preconditioning on Clinical 
Outcomes in CABG Surgery (ERICCA) study70 and the Remote 
Ischemic Preconditioning for Heart Surgery (RIPHeart) study71 
have looked at this issue as well. In both studies, the incidence 
of primary endpoint (death from cardiovascular causes, non-
fatal myocardial infarction, coronary revascularization, or stroke 
for the ERICCA study and composite of death, myocardial 
infarction, stroke, or acute renal failure for the RIPHeart study) 
was similar between diabetic patients assigned to the control 
group and those assigned to the RIPC group.
Nevertheless, the use of propofol—known to interfere with the 
cardioprotective effects of remote ischemic conditioning—in 
both studies might have influenced their results72. Therefore, 
further research and well-designed clinical trials are needed 
to seek whether diabetic myocardium is responsive to the 
cardioprotective effects of RIPC.
Beta-blockers and their cardioprotective effects in diabetes
Beta-blockers are recommended as cardioprotective medica-
tion in patients with coronary artery disease73 and congestive 
heart failure74. Indeed, their use is associated with reduced 
mortality and reduced recurrent myocardial infarction after 
myocardial infarction. Beta-blockers decrease mortality as well 
in patients with chronic heart failure and systolic dysfunction. 
Patients with diabetes often present different cardiovascular 
risk factors. The Diabetes Postoperative Mortality and 
Morbidity (DIPOM) trial evaluated the long-term effects of 
100 mg metoprolol or placebo on mortality and morbidity in 
diabetic patients undergoing major non-cardiac surgery75. This 
study was unable to show the benefit of starting β-blockers in the 
perioperative setting in patients with diabetes. Very recently, 
the relationship between the use of β-blockers and all-cause 
mortality was evaluated in patients with diabetes mellitus and 
those without76. The mortality of diabetic patients taking 
β-blockers was higher compared with those diabetics who did 
not take β-blockers (hazard ratio 1.65, 95% confidence interval 
1.13–2.40; P = 0.009). Similar results were found when only 
β1-selective β-blockers were taken into analysis. However, 
all-cause mortality was significantly lower in non-diabetic 
patients taking β1-selective β-blockers compared with non- 
diabetic participants not taking β-blockers (P = 0.01). Although 
the authors cannot explain the exact reason for these observed 
differences, they hypothesize that adverse effects on glucose 
metabolism (more hypoglycemia and hypoglycemia unaware-
ness in diabetics) and weight gain induced by β-blockers may 
result in an increased risk of mortality.
What is true from a cardioprotective perspective in non- 
diabetics may not necessarily be relevant in patients with diabe-
tes mellitus. Further research in this field is mandatory before 
drawing any firm conclusions.
Aging
Ischemia-reperfusion injury and cardioprotection in the 
aged myocardium
Aging induces structural and functional changes in the heart, as in 
all other human organs, resulting in greater damage of the aging 
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heart owing to the deleterious effects of ischemia-reperfusion 
injury77–79. Moreover, experimental studies have shown 
that the aging myocardium is less responsive to ischemic 
preconditioning80–84. This reduced preconditioning effect in the 
aged myocardium has also been observed with inhalational 
anesthetics85,86.
A recent study specifically investigated the influence of aging 
on the release of cardioprotective humoral factors after RIPC 
and the cardioprotective effects of RIPC on aged myocardium87. 
From the data obtained in this study, it appears that the release 
of humoral factors after RIPC is age-dependent and that the 
RIPC-induced humoral factors are cardioprotective also in the 
aged heart. These results emphasize the complex mechanisms 
involved in the cardioprotective effects of RIPC and might 
partly explain the disappointing observation in large clinical 
trials aiming to show the perioperative cardioprotective effects of 
RIPC70,71.
Studies of perioperative cardioprotection taking into 
account patient’s age
Despite the existing evidence of experimental trials that the 
aged myocardium is less responsive to any type of cardiopro-
tection, few clinical studies have clearly analyzed the possible 
relation between the extent of perioperative cardioprotection 
and age.
From the available clinical data, it is not clear whether consid-
erable cardioprotection can be achieved in the elderly70,88–91. 
Of note, it remains difficult to give an exact definition of “old 
myocardium”. More than the chronological age of the patient, 
conditions that influence the endogenous protective mecha-
nisms of the myocardium might affect the response of the heart 
to various protective mechanisms. Physical activity has been 
shown to be among such protective mechanisms92,93. Future 
trials need to take into account these aspects.
Comedication
Elderly people often take various cardiovascular (and other) 
medications. These treatments alone or in combination may 
interfere with cardioprotective mechanisms. Some of these 
drug therapies have been discussed in this review article. Other 
routinely used medications that have been studied in the con-
text of perioperative cardioprotection and that will be further 
discussed in this review article are (1) statins, (2) angiotensin- 
converting enzyme inhibitors (ACE-Is)/angiotensin receptor 
blockers, (3) calcium channel blockers, and (4) nitrates. 
The interaction of these drugs with some of the periopera-
tive cardioprotective strategies has been studied in different 
trials.
Statins. In recent years, much interest has been given to the 
pleiotropic effects of statins, contributing to their cardioprotec-
tive effects94. The cardioprotective properties of statins have 
been evaluated in numerous trials resulting in a considerable 
number of meta-analyses and systematic reviews. It seems that 
perioperative statin therapy is associated with a lower incidence 
of postoperative myocardial infarction in non-cardiac surgery 
but not in cardiac surgery. The pathophysiology of periop-
erative myocardial ischemia is different in non-cardiac95 and 
cardiac surgery, which may explain the discrepant results 
between the two surgical groups.
Based on the evidence available in 2014, the European 
Society of Cardiology/European Society of Anaesthesiology 
(ESC/ESA) guidelines on non-cardiac surgery have a class I 
recommendation for perioperative continuation of statins, 
favoring statins with a long half-life or extended-release 
formulation. A class IIa recommendation has been given for 
preoperative initiation of statin therapy in patients undergoing 
vascular surgery and ideally this should be performed at least 
2 weeks before surgery96.
Angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers. A large meta-analysis of randomized clinical 
trials of renin–angiotensin–aldosterone system inhibitors in 
patients with hypertension showed that all-cause mortality was 
significantly reduced with these drugs compared with controls97. 
However, the observed treatment effect resulted from the ACE-
Is. This decrease in mortality could not be demonstrated with 
angiotensin receptor blockers97.
Both drugs, when used in the perioperative period, can induce 
mild to severe hypotension, which can be resistant to vasopres-
sors in some patients. Therefore, when these drugs are used 
for hypertension, their withdrawal 24 hours before surgery has 
been recommended. This is a class IIa recommendation from 
ESC/ESA guidelines on non-cardiac surgery96. These guide-
lines recommend continuation of ACE-Is or angiotensin receptor 
blockers under close monitoring during non-cardiac surgery in 
stable patients with heart failure and left ventricular systolic 
dysfunction (IIa).
Calcium channel blockers. Few well-powered studies have 
evaluated the beneficial effects of calcium channel blockers in the 
perioperative period. The safety and efficacy of these drugs have 
been questioned98.
The use of dihydropiridine calcium channel blockers has been 
associated with 30-day mortality in patients with acute or elec-
tive aortic aneurysm surgery99. In this regard, the 2014 ESC/ESA 
guidelines recommend that the continuation or introduction of 
heart rate–reducing calcium channel blockers may be considered 
in patients not tolerating β-blockers96.
Nitrates. In recent years, there has been increasing interest in 
the cardioprotective effects of nitrates. Previous studies have 
shown that intravenous injection of nicorandil can decrease the 
incidence of myocardial injury after percutaneous coronary 
intervention100,101. Otherwise, a single oral dose of nicorandil 
showed cardioprotective effects after coronary angioplasty102. 
The preconditioning actions of nitroglycerin have been demon-
strated in specific clinical scenarios103,104. Leesar et al.103 showed, 
for the first time, that 4-hour intravenous administration of 
nitroglycerin protected human myocardium against ischemia 24 
hours after its administration105. Nevertheless, the endothelial 
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preconditioning effects of a single dose of nitroglycerin are 
lost after a prolonged exposure to nitroglycerin, limiting the 
beneficial effects of long-term prophylactic nitrate therapy106. 
In a small study, its acute administration did not interfere with 
remote ischemic conditioning107. Otherwise, two large clinical 
studies failed to show any possible benefit in terms of mortality 
with the use of nitrates in the setting of acute myocardial injury 
with thrombolytic therapy108,109.
Conclusions
Prevention of perioperative morbidity and mortality is a 
challenge in patients with diabetes and in the elderly. Patients 
with diabetes are at high risk of ischemic heart disease and 
are vulnerable to the effects of myocardial ischemia-reperfusion 
injury. Chronic metformin treatment has shown promising 
results regarding cardiovascular outcome in patients with 
diabetes. Its perioperative cardioprotective effects still need to 
be investigated. Nevertheless, its withdrawal before any surgery 
may not be justified, as the risk of lactic acidosis is extremely 
low. The safety and efficacy of RIPC in the setting of diabetes 
need to be elucidated. Otherwise, β-blockers may not have 
the same beneficial effects in diabetic patients compared with 
non-diabetics. Their use should be carefully evaluated in diabetic 
patients who have a maximum medical treatment.
Advanced age is often associated with cardiovascular morbidity. 
Currently, there is no clear evidence whether elderly patients 
are less responsive to routine perioperative cardioprotective 
strategies. Comedication is often observed in older patients. 
Current evidence strongly supports the continuation of statins 
in the perioperative period. ACE-Is reduce all-cause mortality 
when used for hypertension and should only be stopped 
24 hours before surgery to avoid hypotension.
In conclusion, the translation of cardioprotection into the 
clinical setting where advanced age and various comorbidities 
are common calls for well-designed experimental and clinical 
studies.
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